GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Krka d.d. (WAR:KRK) » Definitions » EBIT

Krka d.d. (WAR:KRK) EBIT : zł1,526 Mil (TTM As of Sep. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Krka d.d. EBIT?

Krka d.d.'s earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was zł334 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was zł1,526 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Krka d.d.'s annualized ROC % for the quarter that ended in Sep. 2023 was 14.63%. Krka d.d.'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 22.89%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Krka d.d.'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 10.68%.


Krka d.d. EBIT Historical Data

The historical data trend for Krka d.d.'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krka d.d. EBIT Chart

Krka d.d. Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 905.54 1,239.64 1,616.79 1,606.14 1,802.10

Krka d.d. Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 307.59 319.37 447.01 426.10 333.68

Competitive Comparison of Krka d.d.'s EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Krka d.d.'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krka d.d.'s EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Krka d.d.'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Krka d.d.'s EV-to-EBIT falls into.



Krka d.d. EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł1,526 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Krka d.d.  (WAR:KRK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Krka d.d.'s annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=1417.072 * ( 1 - 17.96% )/( (7954.028 + 7934.688)/ 2 )
=1162.5658688/7944.358
=14.63 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11741.561 - 846.791 - ( 2940.742 - max(0, 1563.285 - 7338.686+2940.742))
=7954.028

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11085.583 - 904.105 - ( 2246.79 - max(0, 1684.956 - 6755.369+2246.79))
=7934.688

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Krka d.d.'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1334.704/( ( (3213.213 + max(2663.302, 0)) + (3192.763 + max(2590.549, 0)) )/ 2 )
=1334.704/( ( 5876.515 + 5783.312 )/ 2 )
=1334.704/5829.9135
=22.89 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1845.142 + 2279.97 + 86.911) - (846.791 + 0 + 701.93)
=2663.302

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1796.364 + 2307.147 + 158.622) - (904.105 + 0 + 767.479)
=2590.549

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Krka d.d.'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2023 )
=1526.156/14284.884
=10.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Krka d.d. EBIT Related Terms

Thank you for viewing the detailed overview of Krka d.d.'s EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Krka d.d. (WAR:KRK) Business Description

Traded in Other Exchanges
Address
Smarjeska Cesta 6, Novo Mesto, SVN, 8501
Krka d.d. engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resort, and tourist services. The company products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, Oncology; Non-prescription products include Cold and cough products, nasal products, vitamin and minerals, hair care products; and Animal health products include Antimicrobials, Disinfectants, among others. It operates across the European Union, South-East Europe, East Europe region, and Others. The company derives a majority of revenue from the European Union.

Krka d.d. (WAR:KRK) Headlines

No Headlines